Christine N Chang-Halpenny1, Jekwon Yeh2, Winston W Lien3. 1. Radiation Oncologist at the Sunset Medical Center in Los Angeles, CA. christine.n.chang-halpenny@kp.org. 2. Radiation Oncologist at the Cancer Center of Irvine in CA. jyeh.md22@ccoi.org. 3. Radiation Oncologist at the Sunset Medical Center in Los Angeles, CA. winston.w.lien@kp.org.
Abstract
CONTEXT: Glioblastoma multiforme (GBM) is an aggressive neoplasm, with controversy regarding treatment in elderly patients. OBJECTIVE: To review outcomes of elderly patients aged ≥ 65 with newly diagnosed GBM treated with concurrent temozolomide and either standard-course radiotherapy (SRT) or abbreviated-course radiotherapy (ART). DESIGN: Retrospective review from 2003 to 2012. MAIN OUTCOME MEASURE: Survival, comparing treatment regimens. One hundred patients received SRT (median dose = 60 Gy), and 29 received ART (median dose = 35 Gy). O6- methylguanine-DNA methyltransferase (MGMT) status was available for 26 SRT and 13 ART recipients. RESULTS: Median age was 70 years. Median follow-up was 11 months. At analysis, 3 patients were alive. Multivariate analysis of the entire cohort found SRT (hazard ratio [HR] = 0.421, p = 0.0001), Karnofsky Performance Score of 70 or higher (HR = 1.894, p = 0.0031), and more extensive surgery (HR = 0.466, p = 0.0023) were associated with longer survival time, but age was not. Median time to death with SRT was 13 months versus 5.4 months with ART, but the latter had worse prognostic factors, including lower Karnofsky Performance Scores, fewer gross total resections, and higher recursive partitioning analysis class. Recipients of SRT with methylated MGMT promoter had a trend toward longer survival compared with unmethylated MGMT (p = 0.06), but ART recipients had shorter survival with MGMT methylation (p = 0.02). CONCLUSION: Elderly patients with multiple poor prognostic factors given ART had short survival times. Relative to other variables, MGMT status may not predict outcome for these patients.
CONTEXT: Glioblastoma multiforme (GBM) is an aggressive neoplasm, with controversy regarding treatment in elderly patients. OBJECTIVE: To review outcomes of elderly patients aged ≥ 65 with newly diagnosed GBM treated with concurrent temozolomide and either standard-course radiotherapy (SRT) or abbreviated-course radiotherapy (ART). DESIGN: Retrospective review from 2003 to 2012. MAIN OUTCOME MEASURE: Survival, comparing treatment regimens. One hundred patients received SRT (median dose = 60 Gy), and 29 received ART (median dose = 35 Gy). O6- methylguanine-DNA methyltransferase (MGMT) status was available for 26 SRT and 13 ART recipients. RESULTS: Median age was 70 years. Median follow-up was 11 months. At analysis, 3 patients were alive. Multivariate analysis of the entire cohort found SRT (hazard ratio [HR] = 0.421, p = 0.0001), Karnofsky Performance Score of 70 or higher (HR = 1.894, p = 0.0031), and more extensive surgery (HR = 0.466, p = 0.0023) were associated with longer survival time, but age was not. Median time to death with SRT was 13 months versus 5.4 months with ART, but the latter had worse prognostic factors, including lower Karnofsky Performance Scores, fewer gross total resections, and higher recursive partitioning analysis class. Recipients of SRT with methylated MGMT promoter had a trend toward longer survival compared with unmethylated MGMT (p = 0.06), but ART recipients had shorter survival with MGMT methylation (p = 0.02). CONCLUSION: Elderly patients with multiple poor prognostic factors given ART had short survival times. Relative to other variables, MGMT status may not predict outcome for these patients.
Authors: Normand Laperriere; Michael Weller; Roger Stupp; James R Perry; Alba A Brandes; Wolfgang Wick; Martin J van den Bent Journal: Cancer Treat Rev Date: 2012-06-19 Impact factor: 12.111
Authors: Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta Journal: N Engl J Med Date: 2014-02-20 Impact factor: 91.245
Authors: W Roa; P M A Brasher; G Bauman; M Anthes; E Bruera; A Chan; B Fisher; D Fulton; S Gulavita; C Hao; S Husain; A Murtha; K Petruk; D Stewart; P Tai; R Urtasun; J G Cairncross; P Forsyth Journal: J Clin Oncol Date: 2004-03-29 Impact factor: 44.544
Authors: W J Curran; C B Scott; J Horton; J S Nelson; A S Weinstein; A J Fischbach; C H Chang; M Rotman; S O Asbell; R E Krisch Journal: J Natl Cancer Inst Date: 1993-05-05 Impact factor: 13.506
Authors: Randall J Kimple; Sarah Grabowski; Michael Papez; Frances Collichio; Matthew G Ewend; David E Morris Journal: Am J Clin Oncol Date: 2010-06 Impact factor: 2.339
Authors: Nathan S Floyd; Shiao Y Woo; Bin S Teh; Charlotte Prado; Wei-Yuan Mai; Todd Trask; Philip L Gildenberg; Paul Holoye; Mark E Augspurger; L Steven Carpenter; Hsin H Lu; J Kam Chiu; Walter H Grant; E Brian Butler Journal: Int J Radiat Oncol Biol Phys Date: 2004-03-01 Impact factor: 7.038
Authors: Scott R Floyd; Ekkehard M Kasper; Erik J Uhlmann; Ekokobe Fonkem; Eric T Wong; Anand Mahadevan Journal: Front Oncol Date: 2012-10-16 Impact factor: 6.244
Authors: Aisling M Glynn; Guhan Rangaswamy; Julianne O'Shea; Mary Dunne; Roger Grogan; Stephen MacNally; David Fitzpatrick; Clare Faul Journal: Cancer Med Date: 2019-07-04 Impact factor: 4.452